Anti-β2-glycoprotein I autoantibody expression as a potential biomarker for strokes in patients with anti-phospholipid syndrome

被引:8
作者
Ali, Husham Y. M. [1 ]
Abdullah, Zainalabideen A. [1 ]
机构
[1] Univ Mosul, Dept Microbiol & Immunol, Coll Med, Mosul, Iraq
关键词
anti-beta(2)-glycoprotein I; autoantibodies; stroke;
D O I
10.1080/15476910802129638
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Anti-phospholipid syndrome (APS) is an autoimmune disease. Cerebral ischemia associated with APS occurs at a younger age than typical atherothrombotic cerebrovascular disease, is often recurrent, and is associated with high positive IgG anti-phospholipid (GPL) unit levels. This study sought to determine the frequency rates of anti-cardiolip in (aCL) dependent on the presence of beta(2)-GPI, anti-beta(2)-glycoprotein I (alpha beta(2)-GPI), and anti-phosphatidyl serine (aPS) IgG autoantibodies among stroke patients, and thus demonstrate the importance of testing for a alpha(2)-GPI autoantibodies. For these study, stroke patients and control subjects recruited from Mosul, Erbil, and Dohuk provinces in Northeren Iraq between March 2004 and March 2005 were evaluated. All cases were under 50 years-of-age and had no recognizable risk factors. Using ELISA to evaluate the presence of IgG isotype of aCL, a beta(2)-GPI, and aPS autoantibodies in their blood, the results indicated that the frequency of a beta(2)-GPI was 14/50 (28%), aCL was 11/50 (22%) , and aPS was 9/50 (18%) among stroke patients. In contrast, aCL was detected in 2/30 (6.7%) of control subjects; each of the other anti-phospholipid antibodies (APLA) was never observed. Of all the a beta(2)-GPI(+) cases, the incidence of stroke patients having the combined profile of a beta(2)-GPI + aCL was 11/14 (78.6%) and of a beta(2)-GPI + aPS was 9/14 (64.3%). Only 2/14 (14.3%) of these a beta(2)-GPI(+) patients also expressed aCL in the absence of aPS. The frequency of patients expressing all three markers was only 9/14 (64.3 %). In none of the APS/stroke patients were aCL or aPS expressed in the absence of the a beta(2)-GPI. Conversely, a beta(2)-GPI as a sole marker was seen in 3/14 (21.4%) of these patients (i.e., in absence of either other marker). It can be concluded from these studies that the among the three major forms of APLA examined, the presence of a beta(2)-GPI IgG autoantibodies appeared to correlate best with stroke in patients who were concurrently suffering APS.
引用
收藏
页码:173 / 177
页数:5
相关论文
共 25 条
  • [1] ALI HYM, 2006, THESIS U MOSUL IRAQ
  • [2] Arnout J, 1999, THROMB HAEMOSTASIS, V81, P929
  • [3] BEVERS EM, 1991, THROMB HAEMOSTASIS, V66, P629
  • [4] Antiphospholipid antibodies and stroke in young women
    Brey, RL
    Stallworth, CL
    McGlasson, DL
    Wozniak, MA
    Wityk, RJ
    Stern, BJ
    Sloan, MA
    Sherwin, R
    Price, TR
    Macko, RF
    Johnson, CJ
    Earley, CJ
    Buchholz, DW
    Hebel, JR
    Kittner, SJ
    [J]. STROKE, 2002, 33 (10) : 2396 - 2400
  • [5] ANTIPHOSPHOLIPID ANTIBODIES AND CEREBRAL-ISCHEMIA IN YOUNG-PEOPLE
    BREY, RL
    HART, RG
    SHERMAN, DG
    TEGELER, CH
    [J]. NEUROLOGY, 1990, 40 (08) : 1190 - 1196
  • [6] β2-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction -: The Honolulu Heart Program
    Brey, RL
    Abbott, RD
    Curb, JD
    Sharp, DS
    Ross, GW
    Stallworth, CL
    Kittner, SJ
    [J]. STROKE, 2001, 32 (08) : 1701 - 1706
  • [7] The antiphospholipid/cofactor syndromes: A primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays
    Cabral, AR
    Amigo, MC
    Cabiedes, J
    AlarconSegovia, D
    [J]. AMERICAN JOURNAL OF MEDICINE, 1996, 101 (05) : 472 - 481
  • [8] β2-glycoprotein I, the playmaker of the antiphospholipid syndrome
    de Laat, HB
    Derksen, RHWM
    de Groot, PG
    [J]. CLINICAL IMMUNOLOGY, 2004, 112 (02) : 161 - 168
  • [9] Controversies in the antiphospholipid syndrome and stoke
    Gatenby, PA
    [J]. THROMBOSIS RESEARCH, 2004, 114 (5-6) : 483 - 488
  • [10] Gharavi AE, 1999, J IMMUNOL, V163, P2922